Organic-inorganic hybrid nanoparticles controlled delivery system for anticancer drugs
| Parent link: | Iranian Journal of Radiology Vol. 526, iss. 1-2.— 2017.— [P. 380-390] |
|---|---|
| Corporate Authors: | , , |
| מחברים אחרים: | , , , , |
| סיכום: | Title screen The use of organic-inorganic hybrid nanocarriers for controlled release of anticancer drugs has been gained a great interest, in particular, to improve the selectivity and efficacy of the drugs. In this study, iron oxide nanoparticles were prepared then surface modified via diazonium chemistry and coated with chitosan, and its derivative chitosan-grafted polylactic acid. The purpose was to increase the stability of the nanoparticles in physiological solution, heighten drug-loading capacity, prolong the release, reduce the initial burst effect and improve in vitro cytotoxicity of the model drug doxorubicin. The materials were characterized by DLS, ?-potential, SEM, TGA, magnetization curves and release kinetics studies. Results confirmed the spherical shape, the presence of the coat and the advantages of using chitosan, particularly its amphiphilic derivative, as a coating agent, thereby surpassing the qualities of simple iron oxide nanoparticles. The coated nanoparticles exhibited great stability and high encapsulation efficiency for doxorubicin, at over 500 µg per mg of carrier. Moreover, the intensity of the initial burst was clearly diminished after coating, hence represents an advantage of using the hybrid system over simple iron oxide nanoparticles. Cytotoxicity studies demonstrate the increase in cytotoxicity of doxorubicin when loaded in nanoparticles, indirectly proving the role played by the carrier and its surface properties in cell uptake. Режим доступа: по договору с организацией-держателем ресурса |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1016/j.ijpharm.2017.04.061 |
| פורמט: | אלקטרוני Book Chapter |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=655682 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 655682 | ||
| 005 | 20250522123858.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\21941 | ||
| 090 | |a 655682 | ||
| 100 | |a 20170921d2017 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Organic-inorganic hybrid nanoparticles controlled delivery system for anticancer drugs |f M. A. Di [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: p. 389-390 (51 tit.)] | ||
| 330 | |a The use of organic-inorganic hybrid nanocarriers for controlled release of anticancer drugs has been gained a great interest, in particular, to improve the selectivity and efficacy of the drugs. In this study, iron oxide nanoparticles were prepared then surface modified via diazonium chemistry and coated with chitosan, and its derivative chitosan-grafted polylactic acid. The purpose was to increase the stability of the nanoparticles in physiological solution, heighten drug-loading capacity, prolong the release, reduce the initial burst effect and improve in vitro cytotoxicity of the model drug doxorubicin. The materials were characterized by DLS, ?-potential, SEM, TGA, magnetization curves and release kinetics studies. Results confirmed the spherical shape, the presence of the coat and the advantages of using chitosan, particularly its amphiphilic derivative, as a coating agent, thereby surpassing the qualities of simple iron oxide nanoparticles. The coated nanoparticles exhibited great stability and high encapsulation efficiency for doxorubicin, at over 500 µg per mg of carrier. Moreover, the intensity of the initial burst was clearly diminished after coating, hence represents an advantage of using the hybrid system over simple iron oxide nanoparticles. Cytotoxicity studies demonstrate the increase in cytotoxicity of doxorubicin when loaded in nanoparticles, indirectly proving the role played by the carrier and its surface properties in cell uptake. | ||
| 333 | |a Режим доступа: по договору с организацией-держателем ресурса | ||
| 461 | |t Iranian Journal of Radiology | ||
| 463 | |t Vol. 526, iss. 1-2 |v [P. 380-390] |d 2017 | ||
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a iron nanoparticles | |
| 610 | 1 | |a chitosan | |
| 610 | 1 | |a polylactic acid | |
| 610 | 1 | |a controlled release | |
| 610 | 1 | |a doxorubicinchitosan | |
| 610 | 1 | |a железные наночастицы | |
| 610 | 1 | |a хитозан | |
| 610 | 1 | |a полимолочная кислота | |
| 610 | 1 | |a доксорубицин | |
| 701 | 1 | |a Di Martino |b A. |c organic chemist |c research of Tomsk Polytechnic University |f 1984- |g Antonio |3 (RuTPU)RU\TPU\pers\39440 |9 20983 | |
| 701 | 1 | |a Guselnikova |b O. A. |c chemist |c Researcher at Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1992- |g Olga Andreevna |3 (RuTPU)RU\TPU\pers\34478 |9 17861 | |
| 701 | 1 | |a Trusova |b M. E. |c organic chemist |c Associate professor of Tomsk Polytechnic University, Candidate of chemical sciences |f 1982- |g Marina Evgenievna |3 (RuTPU)RU\TPU\pers\31823 |9 15918 | |
| 701 | 1 | |a Postnikov |b P. S. |c organic chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of chemical sciences |f 1984- |g Pavel Sergeevich |3 (RuTPU)RU\TPU\pers\31287 |9 15465 | |
| 701 | 1 | |a Sedlarik |b V. |g Vladimir | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет (ТПУ) |b Физико-технический институт (ФТИ) |b Кафедра прикладной физики (№ 12) (ПФ) |3 (RuTPU)RU\TPU\col\18729 |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет (ТПУ) |b Институт природных ресурсов (ИПР) |b Кафедра технологии органических веществ и полимерных материалов (ТОВПМ) |3 (RuTPU)RU\TPU\col\18659 |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет (ТПУ) |b Институт физики высоких технологий (ИФВТ) |b Кафедра биотехнологии и органической химии (БИОХ) |3 (RuTPU)RU\TPU\col\18693 |
| 801 | 2 | |a RU |b 63413507 |c 20171003 |g PSBO | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.1016/j.ijpharm.2017.04.061 | |
| 942 | |c CF | ||